MECR Protein: A Promising Drug Target for Cancer Therapies (G51102)

Target Name: MECR

NCBI ID: G51102

MECR

MECR Protein: A Promising Drug Target for Cancer Therapies

MECR (MutL1-Enhanced Carbohydrate Recognition) is a protein that is expressed in various cell types of the human body, including blood cells, neurons, and cancer cells. It is a key regulator of the cell cycle and has been implicated in the development and progression of many diseases, including cancer.

One of the most promising aspects of MECR is its potential as a drug target. Its unique ability to recognize and interact with carbohydrates has led to the development of several compounds that have been shown to inhibit MECR and its functions, providing new avenues for the development of cancer therapies.

MECR is a member of the MUTL1 gene family, which is known for its role in regulating the end structure of DNA double strands. Mutations in the MUTL1 gene can lead to structural instability of DNA double-stranded ends, and have been shown to play an important role in tumor occurrence and development. MECR gene mutations will lead to increased expression of MECR protein, which plays a role in tumor occurrence and development.

MECR protein is composed of multiple subunits, including an 伪-helix, a 尾-sheet and a 纬-helix. Its alpha-helical structure enables it to recognize and bind to a variety of carbohydrates, including polysaccharides, glycoproteins, and polysaccharides. The 尾-page and 纬-helix structures of MECR protein enable it to bind to DNA and participate in regulating the cell cycle.

The functions of MECR protein are mainly manifested in regulating the cell cycle, participating in the end structure of DNA double strands, and participating in apoptosis. In the cell cycle, MECR protein plays a key role in mitosis and interphase. During mitosis, the 伪-helical structure of MECR protein will wind up into a tight 尾-sheet-伪 helix structure. During interphase, this structure will unwind into a smaller structure. The loose 伪-helical structure allows MECR protein to bind to DNA.

Another important function of MECR protein is to participate in the end structure of DNA double strands. In DNA double strands, the terminal structures will form 5'-phosphate groups and 3'-hydroxyl groups. These structures play an important role in the stability and accessibility of DNA. MECR protein can recognize and bind to the 5'-phosphate group and 3'-hydroxyl group of DNA, thereby affecting the structure and function of DNA.

MECR protein is also involved in apoptosis. In apoptosis, the 纬-helical structure of MECR protein can bind to DNA, thereby participating in the regulation of apoptosis. The 纬-helical structure of MECR protein plays an important role in the apoptosis signaling pathway, and its mutation can lead to abnormal cell apoptosis.

These functions of the MECR protein make it a very attractive drug target. Since MECR protein is overexpressed in a variety of cancers, the development of drugs targeting MECR protein has become a hot topic in the field of cancer treatment.

At present, some drugs that inhibit the function of MECR protein have entered clinical research, including anti-tumor drugs, anti-inflammatory drugs, and antidepressant drugs. The mechanisms of action of these drugs vary, but they all exploit functional differences in the MECR protein to inhibit its effects.

For example, anti-tumor drugs such as 5-Fu and carboplatin often utilize the DNA-binding function of MECR proteins to inhibit the growth of cancer cells. Anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs usually utilize the 5'-phosphate and 3'-hydroxyl functions of the MECR protein to inhibit the inflammatory response. Antidepressant drugs such as SSRI antidepressants usually utilize the 纬-helical structure of MECR protein to regulate apoptosis.

Although drugs that inhibit the function of MECR protein have entered clinical research, the role of MECR protein in the occurrence and development of cancer still needs further study. Researchers are exploring the mechanism of action of the MECR protein in cancer and looking for new drugs that inhibit the function of the MECR protein.

Protein Name: Mitochondrial Trans-2-enoyl-CoA Reductase

Functions: Catalyzes the NADPH-dependent reduction of trans-2-enoyl thioesters in mitochondrial fatty acid synthesis (fatty acid synthesis type II). Fatty acid chain elongation in mitochondria uses acyl carrier protein (ACP) as an acyl group carrier, but the enzyme accepts both ACP and CoA thioesters as substrates in vitro. Displays a preference for medium-chain over short- and long-chain substrates (PubMed:18479707, PubMed:12654921, PubMed:27817865). May provide the octanoyl chain used for lipoic acid biosynthesis, regulating protein lipoylation and mitochondrial respiratory activity particularly in Purkinje cells (By similarity)

The "MECR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MECR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets